




# 2008 Biotechnology Seminar Series

All seminars begin at 11:00 am



Sept. 22	<b>Jay Ahn</b> CEO Cubiq Inc.	Low-cost CMOS-based biosensor capable of highly sensitive, real-time disease detection
Sept. 25 Room: 5-201	<b>Kyle Chan</b> CTO BiotheryX	From Teratogen to Wonder Drug: The 2 Faces of Thalidomide
Sept. 29	<b>Robert Bender</b> Producer Generic NewCo	Hunting Venture Capitalists and How to Skin and Clean Them
Oct. 3 Room: 5-201	<b>Amy Trejo</b> Section Head, Health Care Proctor and Gamble	Design and Development of Health Care Products
Oct. 7 Room: 7-201	<b>James McSwiggen</b> Sr. Dir., Nucleic Acid R&D Quark Pharmaceuticals,	Killing the Messenger: The Therapeutic Applications of RNA Interference
Nov. 6 Room: 5-201	<b>Bronek Pytowski</b> Sr. Dir., Cell Biol. & Bioimaging ImClone Systems Inc.	Gumming up the works: use of antagonist antibodies in cancer therapy
Nov. 11 Room: 7-201	<b>Dennis Healy</b> Assoc. Dir., Translational Res. Bayer HealthCare	Burden of proof – Clinical development and the regulatory approval process
Nov. 18 Room: 7-201	<b>Lucetta Keifer</b> VP, Quality Systems LGTRC	Path to the Clinic: Regulatory Affairs and cGMP Production
Nov. 14 Room: 7-201	<b>Debbie Wilson</b> COO Qyntessa Biologics	Path to the Clinic: Path Overview and Preclinical Development